Congratulations to Charles and Lilly on the BRIDGE Discovery grant!

We’re happy to announce that Charles and Lilly received the BRIDGE Discovery supporting HT-DISCOVER, an exciting new technology for detecting genome editing off-targets. HT-DISCOVER is a drop-in technology that works even in established genome editing workflows, enabling safer and more effective therapies. With the support of BRIDGE Discovery, Charles and Lilly will bring this innovative technology to market in a future spin-off.

Stay tuned for more information!

For potential collaborations and partnerships involving HT-DISCOVER, please contact Jacob Corn (jacob.corn@biol.ethz.ch) and Lilly van de Venn (lilly.vandevenn@biol.ethz.ch).